Abstract
Background From a cohort study, we developed two scores to discriminate coronavirus 2019 (COVID-19) from dengue and other febrile illnesses (OFIs).
Methods All subjects suspected of COVID-19 who attended the SARS-CoV-2 testing center of Saint-Pierre hospital, Reunion, between March 23 and May 10, 2020, were assessed for identifying predictors of both infectious diseases from a multinomial logistic regression model. Two scores were developed after weighting the odd ratios then validated by bootstrapping.
Results Over 49 days, 80 COVID-19, 60 non-severe dengue and 872 OFIs were diagnosed. The translation of the best fit model yielded two scores composed of 11 criteria: contact with a COVID-19 positive case (+3 points for COVID-19; 0 point for dengue), return from travel abroad within 15 days (+3/-1), previous individual episode of dengue (+1/+3), active smoking (−3/0), body ache (0/+5), cough (0/-2), upper respiratory tract infection symptoms (−1/-1), anosmia (+7/-1), headache (0/+5), retro-orbital pain (−1/+5), and delayed presentation (>3 days) to hospital (+1/0). The area under the receiver operating characteristic curve was 0.79 (95%CI 0.76-0.82) for COVID-19 score and 0.88 (95%CI 0.85-0.90) for dengue score. Calibration was satisfactory for COVID-19 score and excellent for dengue score. For predicting COVID-19, sensitivity was 97% at the 0-point cut-off and specificity 99% at the 10-point cut-off. For predicting dengue, sensitivity was 97% at the 3-point cut-off and specificity 98% at the 11-point cut-off.
Conclusions The COVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue from OFIs in the context of SARS-CoV-2 testing center during a co-epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients medical records were retrospectively reviewed and anonymized data were collected in standardized forms according to the MR-004 procedure of the Commission Nationale de l'Informatique et des Libertes (the French Information Protection Commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of CHU Reunion and anonymized data were registered on the Health Data Hub (N F20201021104344/October, 2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The revision is motivated by resubmisison of our paper and the reanalysis of two supplemental tables to provide more data (use in Stata) of diagti with corrections of nul boxes sf option to obtain more data at both extreme cut-off values)
Data Availability
Data are entirely accessible through a data repository through the publication of this article.
List of abbreviations (alphabetic order)
- aOR
- Adjusted odds ratio
- AUC
- Area under receiver operating characteristic curve
- CIR
- Cumulative incidence rate (attack rate)
- CNR
- Centre national de reference
- COVID-19
- Coronavirus 2019
- DENV
- Dengue virus
- FN
- False negative
- FP
- False positive
- ICU
- Intensive Care Unit
- LR-
- Negative likelihood ratio
- LR+
- Positive likelihood ratio
- MHL test
- Multinomial Hosmer-Lemeshow test
- MLR
- Multinomial logistic regression
- NPV
- Negative predictive value
- OFIs
- Other febrile illnesses
- PPV
- Positive predictive value
- RT-PCR
- Reverse transcription – polymerase chain reaction
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- SpO2
- Pulse oxymetry
- TN
- True negative
- TP
- True positive
- UDACS
- Unite de dépistage ambulatoire du coronavirus sud
- URTI
- Upper respiratory tract infection
- VOCs
- variants of concerns
- 95% CI
- 95% confidence interval
